CXCR4 and head and neck squamous cell carcinoma: Interestingly, a large percent of HNSCC patients could be candidates to targeted nanotoxin therapy since in our 17-patient cohort, 88.2% were positive for the CXCR4 receptor, 94% of them expressed GSDME in tumor tissue, whereas 87% of GSDME+ tumors also co-expressed CXCR4.